Updates in the diagnosis and treatment of malignant pleural mesothelioma

Katzman, Daniel; Sterman, Daniel H.

doi:10.1097/mcp.0000000000000489

Cited by 27 publications

(20 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Italy banned asbestos extraction, use, and commercialization in 1992 (Italian Law 257/92) and it is thus important to monitor the trend of MPM occurrence to detect the effects of such a ban. The large number of MPM cases expected in the next years is of particular concern due to the extremely poor prognosis of this condition and the current lack of effective therapeutic options [20].…”

Section: Introductionmentioning

confidence: 99%

Predictions of Mortality from Pleural Mesothelioma in Italy After the Ban of Asbestos Use

Oddone

Bollon

Nava

et al. 2020

IJERPH

View full text Add to dashboard Cite

Even if the epidemic of malignant pleural mesothelioma (MPM) is still far from being over worldwide, the health effects of regulations banning asbestos can be evaluated in the countries that implemented them early. Estimates of MPM future burden can be useful to inform and support the implementation of anti-asbestos health policies all around the world. With this aim we described the trends of MPM deaths in Italy (1970–2014) and predicted the future number of cases in both sexes (2015–2039), with consideration of the national asbestos ban that was issued in 1992. The Italian National Statistical Institute (ISTAT) provided MPM mortality figures. Cases ranging from 25 to 89 years of age were included in the analysis. For each five-year period from 1970 to 2014, mortality rates were calculated and age–period–cohort Poisson models were used to predict future burden of MPM cases until 2039. During the period 1970–2014 a total number of 28,907 MPM deaths were observed. MPM deaths increased constantly over the study period, ranging from 1356 cases in 1970–1974 to 5844 cases in 2010–2014. The peak of MPM cases is expected to be reached in the period 2020–2024 (about 7000 cases). The decrease will be slow: about 26,000 MPM cases are expected to occur in Italy during the next 20 years (2020–2039). The MPM epidemic in Italy is far from being concluded despite the national ban implemented in 1992, and the peak is expected in 2020–2024, in both sexes. Our results are consistent with international literature.

show abstract

Section: Introductionmentioning

confidence: 99%

Predictions of Mortality from Pleural Mesothelioma in Italy After the Ban of Asbestos Use

Oddone

Bollon

Nava

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…MPM can be of epithelioid, biphasic or sarcomatoid histotype. The sarcomatoid histotype is considered to be most aggressive followed by the biphasic and epithelioid type, irrespective of therapy 4,5 …”

Section: Introductionmentioning

confidence: 99%

Cell and extracellular matrix interaction models in benign mesothelial and malignant pleural mesothelioma cells in 2D and 3D in‐vitro

Jagirdar

Papazoglou

Pitaraki

et al. 2020

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is an aggressive tumour that grows in the pleural cavity. MPM spheroids released in the pleural fluid can form new tumour foci. Cell–cell, cell–extracellular matrix (ECM) interactions in 2D and 3D impact malignant cell behaviour during cell adhesion, migration, proliferation and epithelial–mesenchymal transition (EMT). In this study, epithelioid, biphasic and sarcomatoid MPM cell types as well as benign mesothelial cells were tested with regards to the above phenotypes. Fibronectin (FN) and homologous cell‐derived extracellular matrix (hcd‐ECM) treated substratum differentially affected the above phenotypes. 3D MPM spheroid invasion was higher in FN‐collagen matrices in the epithelioid and biphasic cells, while 3D cell cultures of epithelioid and sarcomatoid MPM cells in FN‐collagen showed a higher contractility compared to hcd‐ECM‐collagen. Cell aggregates demonstrated invasive behaviour in hcd‐ECM matrices alone. Our results suggest that ECM and the dimensionality affect malignant cell behaviour during cell culture studies.

show abstract

“…Among all the mesothelioma patients, the median expression of fibulin-3 and HMGB1 was 4 (3-4) and 7 (3)(4)(5)(6)(7)(8)(9)(10)(11)(12), separately (Fig. 2).…”

Section: Fibulin-3 and Hmgb1 Expression Are Not Different Between Submentioning

confidence: 95%

“…Tumor size, grade, and lymph node status were correlated with prognosis for patients of mesothelioma. Clinical treatments with chemotherapy, surgery, radiation, and novel therapies have been associated with prolonged survival time in mesothelioma patients 10 . Previous studies 11,12 found that BAP1 mutation and Ki-67 index > 5% were associated with prolonged survival time of malignant mesothelioma, based on tissue microarray (TMA) method.…”

mentioning

confidence: 99%

Overexpression of fibulin-3 in tumor tissue predicts poor survival of malignant mesothelioma patients from hand-spinning asbestos exposed area in eastern China

Jiang

Shen

Ying

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Fibulin-3 is an extracellular matrix glycoprotein widely expressed in various tissues. Tissue fibulin-3 expression have never been reported in association with prognosis of mesothelioma. Hence, we sought to determine the association between fibulin-3 expression and mesothelioma survival. We made a tissue microarray, which was comprised of cancer and normal tissue from mesothelioma patients (n = 82) during the period 1998–2017 in China. Fibulin-3 and HGMB1 expression were analyzed by immunohistochemistry method. Kaplan–Meier method and Cox proportional hazard models were used for analyzing survival data. Overall, 61 cases (74.4%) were female; 90.2% were of epithelioid type; the median overall survival time was 12.5 months. Fibulin-3 and HMGB1 were highly expressed in tumor tissue rather than adjacent tissue. The expression of fibulin-3 in tissue was correlated with that of HMGB1 (r = 0.32, P = 0.003). High expression of fibulin-3 in tumor tissue could predict poor survival in patients with mesothelioma (P = 0.02). This remained true in a multivariate model, with a significant hazard ratio of 1.91. We demonstrated that fibulin-3 in tumor tissue was a novel biomarker of poor survival of mesothelioma, suggesting it may be a relevant target for therapeutic intervention.

show abstract

Updates in the diagnosis and treatment of malignant pleural mesothelioma

Cited by 27 publications

References 48 publications

Predictions of Mortality from Pleural Mesothelioma in Italy After the Ban of Asbestos Use

Predictions of Mortality from Pleural Mesothelioma in Italy After the Ban of Asbestos Use

Cell and extracellular matrix interaction models in benign mesothelial and malignant pleural mesothelioma cells in 2D and 3D in‐vitro

Overexpression of fibulin-3 in tumor tissue predicts poor survival of malignant mesothelioma patients from hand-spinning asbestos exposed area in eastern China

Contact Info

Product

Resources

About